Stockscreener 앱 받기
15.25
1.33%
0.20
시간 외 거래:
15.25
전일 마감가:
$15.05
열려 있는:
$15.12
하루 거래량:
1.09M
Relative Volume:
0.93
시가총액:
$1.70B
수익:
$-665.00K
순이익/손실:
$-150.11M
주가수익비율:
-10.12
EPS:
-1.5071
순현금흐름:
$-124.53M
1주 성능:
+13.30%
1개월 성능:
+14.79%
6개월 성능:
+28.48%
1년 성능:
+186.12%
1일 변동 폭
$15.03
$15.57
1주일 범위
$13.12
$16.08
52주 변동 폭
$4.80
$18.61
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
명칭
Amylyx Pharmaceuticals Inc
전화
617-682-0917
주소
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
15.25 | 1.69B | -665.00K | -150.11M | -124.53M | -1.5071 |
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.87 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.56 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.26 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
551.47 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-03 | 개시 | Stifel | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-06-24 | 개시 | Guggenheim | Buy |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2025-05-30 | 개시 | TD Cowen | Buy |
| 2025-04-07 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-11-18 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-03-18 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-11 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-07-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-01-05 | 개시 | BofA Securities | Buy |
| 2022-05-25 | 개시 | Citigroup | Buy |
| 2022-04-01 | 다운그레이드 | Goldman | Buy → Neutral |
모두보기
Amylyx Pharmaceuticals Inc 주식(AMLX)의 최신 뉴스
Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape - Yahoo Finance
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026 - BioSpace
Amylyx (NASDAQ: AMLX) director receives 24,372 stock options grant - Stock Titan
Amylyx (AMLX) director Karen Firestone receives 24,372 stock options grant - Stock Titan
Amylyx (NASDAQ: AMLX) director receives 24,372-share stock option grant - Stock Titan
Amylyx (NASDAQ: AMLX) director awarded 24,372 stock options at $14.31 strike - Stock Titan
Amylyx (AMLX) director Paul Fonteyne receives grant of 24,372 stock options - Stock Titan
Claim your share of the $6.5M Amylyx Pharmaceuticals securities class action settlement - Claim Depot
Post-bariatric hypoglycemia toll, avexitide trial design at ENDO 2026 - Stock Titan
H.C. Wainwright reiterates Amylyx stock rating on PBH trial insights By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Amylyx stock rating on PBH trial insights - Investing.com
Amylyx earnings on deck ahead of pivotal avexitide trial data By Investing.com - Investing.com Nigeria
Amylyx Pharmaceuticals eyes phase 3 AVEXITIDE readout as 2027 launch comes into focus - MSN
Amylyx Pharmaceuticals (NASDAQ: AMLX) investors approve directors, auditor and say-on-pay - Stock Titan
A Look At Amylyx Pharmaceuticals (AMLX) Valuation After Its Recent Share Price Rebound - Yahoo Finance
AMLX Stock Price, Quote & Chart | AMYLYX PHARMACEUTICALS INC (NASDAQ:AMLX) - ChartMill
Amylyx Pharmaceuticals (AMLX) Gains 3.36% as Shares Approach ResistanceWatchlist Stock Ideas - thelegaladvocate.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biohaven Ltd. (BHVN) and Immix Biopharma (IMMX) - The Globe and Mail
Amylyx director Karen Firestone purchases $51,338 of common stock. By Investing.com - Investing.com Nigeria
Amylyx director Karen Firestone purchases $51,338 of common stock. - Investing.com
Director Karen Firestone adds Amylyx Pharmaceuticals (AMLX) shares - Stock Titan
Amylyx gets FDA fast track status for ALS treatment - MSN
Amylyx Pharmaceuticals (AMLX) Slips 2.5% as Biotech Sector Faces Renewed ScrutinyAAII Bullish - thelegaladvocate.com
Amylyx Stock: Why the Full Pipeline Story Matters - MarketBeat
Guggenheim Initiates Coverage of Amylyx Pharmaceuticals (AMLX) with Buy Recommendation - MSN
Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer FRATES JAMES M - Moomoo
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 2026 Results and Pipeline Progress - Insider Monkey
Amylyx Pharmaceuticals, Inc.Common Stock (NQ: AMLX - FinancialContent
Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation - BioSpace
Teva Pharmaceutical (TEVA) Reports Q1 Beat, Plans Amylyx Deal - Yahoo Finance
Number of shareholders of Amylyx Pharmaceuticals, Inc. – BOATS:AMLX - TradingView
Perceptive group holds 8.28M shares of Amylyx (AMLX) in Schedule 13G/A - Stock Titan
Amylyx publishes phase 2 Wolfram syndrome trial results - Investing.com
Amylyx publishes phase 2 Wolfram syndrome trial results By Investing.com - Investing.com Nigeria
Contributor: Fuel drug development, not Big Pharma's profits - AOL.com
B of A Securities Maintains Amylyx Pharmaceuticals (AMLX) Buy Recommendation - MSN
Amylyx Pharmaceuticals Inc (AMLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Amylyx Pharmaceuticals Inc 주식 (AMLX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Klee Justin B. | Co-Chief Executive Officer |
Mar 02 '26 |
Sale |
14.47 |
29,282 |
423,760 |
3,334,616 |
| Cohen Joshua B | Co-Chief Executive Officer |
Mar 02 '26 |
Sale |
14.48 |
29,282 |
424,120 |
3,334,683 |
| Bedrosian Camille L | Chief Medical Officer |
Mar 02 '26 |
Sale |
14.58 |
6,461 |
94,205 |
169,295 |
| FRATES JAMES M | Chief Financial Officer |
Mar 02 '26 |
Sale |
14.52 |
7,909 |
114,851 |
165,638 |
| Mazzariello Gina | Chief Legal Officer |
Mar 02 '26 |
Sale |
14.52 |
6,844 |
99,378 |
134,430 |
0.95%
1.13%
자본화:
|
볼륨(24시간):